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Abstract
Introduction Myocardial injury is frequently unrecognized in
intensive care unit (ICU) patients. Cardiac troponin I (cTnI), a
surrogate of myocardial injury, has been shown to correlate with
outcome in selected groups of patients. We wanted to
determine if cTnI level measured upon admission is an
independent predictor of mortality in a heterogeneous group of
critically ill medical patients.
Methods We conducted a prospective observational cohort
study; 128 consecutive patients admitted to a medical ICU at a
tertiary university hospital were enrolled. cTnI levels were
measured within 6 h of admission and were considered positive
(>0.7 ng/ml) or negative. A variety of clinical and laboratory
variables were recorded.
Results Both cTnI positive and negative groups were similar in
terms of age, sex and pre-admission co-morbidity. In a univariate
analysis, positive cTnI was associated with increased mortality
(OR 7.0, 95% CI 2.44–20.5, p < 0.001), higher Acute
Physiology and Chronic Health Evaluation (APACHE) II scores
and a higher rate of multi-organ failure and sepsis. This
association between cTnI and mortality was more pronounced
among elderly patients (>65 years of age). Multivariate analysis
controlling for APACHE II score revealed that elevated cTnI
levels are not independently associated with 28-day mortality.
Conclusion In critically ill medical patients, elevated cTnI level
measured upon admission is associated with increased
mortality rate. cTnI does not independently contribute to the
prediction of 28-day mortality beyond that provided by APACHE
II.
Introduction
Assessing the severity of illness and outcome of critically ill
patients is important as it influences management strategies
and resource allocation. Historically, research aimed at deter-
mining factors associated with intensive care unit (ICU) mor-
tality focused on individual risk factors and the development of
multivariable prediction scores. These investigations consist-
ently suggested the importance of organ system failure as
strong predictors of both ICU and hospital mortality [1-4].
Over the past decade, several studies indicated that cardiac
dysfunction is a frequent and important factor in determining
the outcome of critically ill patients [5,6]. The pathophysiology
of myocardial injury in critically ill patients is believed to be mul-
tifactorial, including the underlying disease process, hypox-
emia and acidosis as well as therapeutic maneuvers [7,8]. It is
estimated that as many as 15% of ICU admissions are compli-
cated by some degree of myocardial injury and as many as
85% of patients with sepsis may have raised cardiac troponin
[5,9]. Elevated serum levels of cardiac troponin I (cTnI), a myo-
cardial regulatory protein of the thin actin filament, are consid-
ered highly sensitive and specific indicators of myocardial
injury [10]. Serial measurement of cTnI is routinely used in the
evaluation of patients with acute coronary syndromes (ACS)
for diagnostic and prognostic purposes [10-12]. Several stud-
ies have assessed the prognostic value of elevated cTnI in crit-
ically ill patients without ACS. While some suggested that
cTnI levels correlate with myocardial damage and poor out-
come, others could not confirm this association [6,13-17].
Because cTnI elevation reflects organ failure (i.e. myocardial
injury) its role as an additional marker of severity of illness and
outcome is biologically plausible; however, limited information
is available regarding the relative significance of cTnI elevation
as an independent predictor of mortality in relation to the
Acute Physiology And Chronic Health Evaluation (APACHE) II
score. We hypothesized that elevated cTnI will not contribute
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to the mortality prediction provided by the multivariable
APACHE II score. Therefore, we conducted a prospective
cohort study in which the main purpose was to determine
whether cTnI, measured upon admission, is an independent
predictor of mortality in a heterogeneous group of critically ill
medical patients.
Materials and Methods
Study location and population
The study was conducted within the medical ICU (MICU, eight
beds) of Soroka University Medical Center, Beer-Sheva, Israel,
a tertiary university hospital in Israel. All patients admitted to
the MICU during a nine-month period (September 2002 to
June 2003) were evaluated prospectively. The nursing staff
and the physicians providing care for the patients in the MICU
were completely blinded to the troponin results. A total of 128
consecutive patients were enrolled in this observational cohort
study. All definitions were determined prospectively. The defi-
nitions used for sepsis, severe sepsis and organ failure were
those used by the Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis (PROWESS) investi-
gators [18]. Patients diagnosed with ACS, defined as unsta-
ble angina, typical chest pain, ischemic ECG changes or
cardiogenic pulmonary edema were excluded as well as
patients requiring chronic hemodialysis or patients who under-
went major surgery during the month preceding admission (in
order to exclude peri-operative myocardial injury). The Ethics
Committee of the Soroka University Medical Center approved
the study protocol prior to its initiation.
Data collection
One of the investigators who did not participate in routine
patient care made daily rounds in the ICU recording relevant
data from patient medical records and the hospital mainframe
computer for reports of laboratory and microbiologic data. A
complete history and physical examination was recorded on
each patient enrolled in the study. APACHE II score was cal-
culated based on the worst values for the first 24 h after ICU
admission. Serum levels of cTnI were measured within 6 h of
admission. The commercial assay AxSYM Troponin-I (Abbott
laboratories, Abbott Park, Illinois, USA), a micro particle
enzyme immunoassay, was used to determine cTnI levels. The
assay characteristics were as follows: detection limit 0.3 ng/
ml; analytical range 0–50 ng/ml; assay coefficient of variation
(CV) range 5.2–7.8%. The cTnI cutoff is 0.7 ng/ml with a CV
of 10%. Thus any cTnI blood level > 0.7 ng/ml was considered
abnormal and indicative of myocardial injury. The primary end
point was 28-day mortality. Secondary end points included
days on mechanical ventilation, length of stay, and the number
of failing organs.
Statistical analysis
Continuous variables' data are expressed as mean value ± SD.
Bi-variate hypotheses involving continuous variables were
tested with a t-test for independent variables with normal dis-
tribution and Mann-Whitney test for variables with abnormal
distribution. Normality of the data was tested with a one-sam-
ple Kolmogorov-Smirnov test to indicate the appropriateness
of parametric testing. Categorical variables are expressed as
percentage; comparisons between groups were made using
the chi square test. Logistic regression analysis was used to
identify independent variables associated with death. Varia-
bles that were associated with mortality in univariate analysis
were considered for inclusion in the model, whereas parame-
ters already incorporated into the APACHE-II score, such as
age, creatinine level and mean arterial pressure were not
included. Cumulative survival curves were constructed using
the Kaplan-Meier method and compared with the log-rank test.
Results were considered significant at p < 0.05. Statistical
analysis was performed with the SPSS 11.5 statistical pack-
age (SPSS Inc. Chicago, IL, USA).
Results
A total of 128 patients met inclusion criteria and were evalu-
ated during the study period. Demographic and clinical char-
acteristics of the study patients enrolled are shown in Table 1.
The mean age of the study population was 53.9 ± 19 years
and 68% were male. There was no significant difference
between the cTnI positive and negative groups in terms of
background illnesses; ischemic heart disease (20% versus
12%, p = 0.2), chronic obstructive pulmonary disease
(COPD; 17% versus 12%, p = 0.43), diabetes mellitus (31%
versus 17%, p = 0.08), arterial hypertension (34% versus
26%, p = 0.34) or malignancy (6% versus 3%, p = 0.61).
Stratifying the patients according to the absence or presence
of cTnI elevation revealed that of the various causes of admis-
sion, only sepsis was associated with elevated troponin (p =
0.008). Patients with elevated cTnI had a significantly higher
APACHE II score (p < 0.001), required longer duration of
mechanical ventilation (p = 0.004) and their mortality rate
increased from 9.7% to 42.9% (OR 7.0, 95%CI 2.68–18.3, p
< 0.001). Clinical variables upon admission, particularly vaso-
pressor requirement, did not correlate with cTnI levels.
Although creatinine levels were higher in the cTnI group, none
of the patients required renal replacement therapy.
Table 2 shows demographic and clinical information of the
study population stratified according to outcome. Patients
who died had higher cTnI levels (p < 0.001), were significantly
older (p = 0.001), had greater APACHE II scores (p = 0.001)
and longer duration of mechanical ventilation (p < 0.001). In
contrast, the cause of admission was not associated with dif-
ferences in mortality rate. Of the clinical variables evaluated
upon admission only mean arterial pressure (p = 0.006), cre-
atinine level (p = 0.004) and vasopressor requirement were
significantly associated with higher mortality (p = 0.02).
Among elderly (older than 65 years) patients (n = 49) with ele-
vated cTnI levels, the 28-day mortality rate was 10/15 patients
(66.7%), while the mortality rate among elderly patients withAvailable online http://ccforum.com/content/9/4/R390
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normal cTnI levels was only 4/34 patients (11.8%). This pat-
tern was observed also in the younger patients, but to a lesser
extent. Kaplan-Meier survival analysis in the younger and older
age groups is shown in Fig. 1a,b. Log-rank tests for both
groups were statistically significant: 0.04 and <0.001,
respectively.
The results of the multivariate analysis (logistic-regression) are
shown in Table 3. The two variables that were included in the
final model were cTnI and APACHE II; both highly correlated
with mortality in univariate analysis. Elevated cTnI levels were
not found to be an independent predictor of mortality regard-
less of APACHE II score (OR 2.8, 95% CI 0.87–9.2, p =
0.085). Multivariate analysis of the subgroup of patients admit-
ted without sepsis (n = 82) reveals that while APACHE II
remained significantly associated with 28-day mortality (OR
1.2, 95% CI 1.03–1.28 per point increment), abnormal cTnI
level was not (OR 1.2, 95% CI 0.21–7.1).
Discussion
We found that in critically ill medical patients, elevated cTnI is
associated with increased mortality and longer duration of
mechanical ventilation. cTnI does not, however, independently
contribute to the prediction of 28-day mortality beyond that
provided by APACHE II.
Cardiac troponin I and T are the most specific and sensitive
laboratory markers of myocardial cell injury and may be ele-
vated in patients presenting with many conditions other than
acute coronary syndrome [9,11]. Elevated cTnI levels also cor-
relate with decreased left ventricular function in both coronary
and non-coronary patients [13,16]. Cardiac dysfunction dur-
ing sepsis is fairly well documented and has been associated
with poor prognosis [5]. Moreover, a small recent study evalu-
ated the value of brain natriuretic peptide (BNP) plasma levels
as a marker of systolic myocardial dysfunction during severe
sepsis [19]. This study suggested that systolic dysfunction is
present in 44% of patients with severe sepsis, BNP is useful
in its detection and high plasma levels of BNP are associated
with poor outcome [19]. It remains unclear though whether, in
this context, elevated cTnI reflects reversible or irreversible
myocardial damage [7,9]. Our data indicate that in patients
over 65 there is a stronger correlation between elevated cTnI
and mortality, which can probably be attributed to the extent,
and possibly irreversibility, of myocardial damage in this age
group. An interesting finding of this study was that most
deaths among younger patients occurred within the first five
Table 1
Background characteristics of study population, according to elevated troponin result
All (n = 128)a cTnI positive (n = 35)a cTnI negative (n = 93)a p-value
Age (years) 53.9 ± 19 58.7 ± 18.6 52.1 ± 19 0.08
Older than 65 years 49 (38) 15 (43) 34 (37) 0.51
Male 68 (53.1) 19 (54.3) 49 (52.7) 0.87
APACHE II 15.3 ± 8.9 22.6 ± 10 12.7 ± 6.8 <0.001b
Cause of admission
Sepsis 46 (35.9) 19 (54.3) 27 (29) 0.008
Respiratory failure 35 (27.3) 6 (17.1) 29 (31.2) 0.112
Poisoning/drug overdose 10 (7.8) 3 (8.6) 7 (7.5) 0.665
GI hemorrhage 6 (4.7) 2 (5.7) 4 (4.3) 0.844
Miscellaneous 31 (24.2) 5 (14.3) 26 (28) 0.108
Parameters upon admission
Maximal temperature 37.9 ± 1.1 38.2 ± 1.3 37.8 ± 1 0.03b
Minimal mean arterial pressure 70.6 ± 21.7 63.2 ± 15.4 73.2 ± 23 0.02
White blood cell count (×1000) 14.9 ± 8.5 15.6 ± 7.8 14.5 ± 8.8 0.54
Creatinine (µmol/l) 142 ± 133 177 ± 106 124 ± 142 <0.001b
Use of pressors 48 (37.5) 17 (48.6) 31 (33.3) 0.11
28-day mortality 24 (18.8) 15 (42.9) 9 (9.7) <0.001
Length of stay (ICU) 3.3 ± 28.5 6.4 ± 6.6 2.2 ± 33.1 0.07b
Days on mechanical ventilation 3.7 ± 5.4 3.2 ± 5.1 5.4 ± 6.0 0.004b
aNumbers are n, percentages (in parentheses) or mean ± SD, as appropriate. bMan-Whitney test was applied due to abnormality of the data 
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days, whereas in the elderly group the majority of deaths
(60%) occurred after this time frame. This data may suggest
that younger patients who survive the initial insult do relatively
well. Our study, however, was not designed nor powered to
address the effect of age on outcome.
Several studies have addressed the prognostic value of ele-
vated cTnI in non-coronary patients. In selected groups such
as COPD and hemodyalisis patients, elevated cTnI correlated
with poor outcome [20,21]. A study in emergency department
patients has shown that there is a significant correlation
between cTnI elevation and outcome. APACHE II is not pro-
vided, however, nor were the patients stratified by cause of
admission. Therefore, no comparison between this study and
ours could be performed [17]. Relos et al. [22], evaluating sur-
gical ICU patients, suggested that moderate elevation of
serum troponin I, which are below the threshold required to
diagnose overt myocardial infarction, may reflect ongoing myo-
cardial injury in the critically ill and are associated with a higher
mortality rate and longer hospital and ICU length of stay. To
the best of our knowledge, only one study suggested an inde-
pendent predictive value of elevated cTnI after controlling for
severity of illness assessed by APACHE II [23]. A strong cor-
relation between mortality and elevated cTnI in critically ill
medical patients without coronary disease was shown in this
study. The sample size was rather small (58 patients), how-
ever, and the majority of patients had sepsis (88%), which lim-
its the interpretation of these results. In contrast to these
studies, Kollef et al. [6] suggested that serial measurements of
cTnI do not independently contribute to the prediction of hos-
pital mortality beyond that provided by clinically recognized
cardiac dysfunction. Differences in design and patient mix pre-
Table 2
Background characteristics of study population, according to outcome
All (n = 128)a Alive (n = 104)a Dead (n = 24)a p value
Age (years) 53.9 ± 19 51.6 ± 19.4 64 ± 13.6 0.001
Male 68 (53.1) 57 (54.8) 11 (45.8) 0.427
APACHE II 15.3 ± 8.9 13.6 ± 7.5 22.7 ± 10.9 <0.001b
Cause of admission
Sepsis 46 (35.9) 34 (32.7) 12 (50) 0.111
Respiratory failure 35 (27.3) 27 (26) 8 (33.3) 0.465
Poisoning / drug overdose 10 (7.8) 10 (9.6) 0 0.206
GI hemorrhage 6 (4.7) 5 (4.8) 1 (4.2) 1.0
Miscellaneous 31 (24.2) 28 (26.9) 3 (12.5) 0.137
Parameters upon admission
Maximal temperature 37.9 ± 1.1 37.8 ± 1.1 38.1 ± 1.4 0.111b
Minimal mean arterial pressure 70.6 ± 21.7 73.1 ± 22.1 59.5 ± 15.9 0.006
White blood cell count (×1000) 14.8 ± 8.5 14.7 ± 8.1 15.4 ± 10.2 0.723
Creatinine (µmol/l) 133 ± 133 133 ± 142 159 ± 88 0.004b
Use of pressors 48 (37.5) 34 (32.7) 14 (58.3) 0.02
cTnI > 0.7 35 (27.3) 10 (19.2) 15 (62.5) <0.001
Length of stay (ICU) 3.3 ± 28.5 2.7 ± 31.5 6.3 ± 5.9 0.045b
Days on mechanical ventilation 3.7 ± 5.4 3.1 ± 5.2 6 ± 5.7 <0.001b
aNumbers are n, percentages (in parentheses) or mean ± SD, as appropriate. bMan-Whitney test was applied due to abnormality of the data 
distribution. APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit. GI, Gastrointestinal hemorrhage
Table 3
Results of logistic regression analysis for mortality (n = 128)
Variable Coefficient Standard error OR 95% CI of OR p-value
cTnI 1.04 0.6 2.82 0.87–9.2 0.085
APACHE II 0.09 0.03 1.094 1.02–1.17 0.009Available online http://ccforum.com/content/9/4/R390
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clude meaningful comparisons between this study and ours.
Our observation that cTnI elevation is not an independent pre-
dictor of mortality is not surprising because troponin reflects a
single system malfunction while the multivariable APACHE II
reflects several highly relevant systems in the context of criti-
cally ill patients. It is, therefore, unlikely that a single assay will
provide an independent additional value beyond that provided
by APACHE II. Nonetheless, our finding that cTnI elevation is
an important marker of severity of illness and is associated
with high mortality rate is still clinically relevant, particularly in
view of the fact that the Kaplan-Meier analysis indicates that
the discriminative effect of cTnI elevation is evident from the
first day.
The present study included a relatively small number of
patients, limiting the significance of post-hoc subgroup analy-
sis and our ability to identify other independent determinants
of early mortality. The fact that the frequency of ischemic heart
disease (IHD) was similar among cTnI positive patients and
cTnI negative patients supports the assumption that the ele-
vated cTnI in our study should not be attributed to ACS. As we
did not systematically perform echocardiography or evaluation
of coronary flow in these patients, more objective assessment
of coronary anatomy and myocardial function is not available.
Therefore, any correlation between cTnI levels, in these
patients, and irreversible myocardial dysfunction or ACS
remains deductive. As indicated earlier, however, elevated
cTnI has been previously shown to correlate with left ventricu-
lar function. In our study, cTnI was sampled only once upon
admission. Even though the time course and kinetics of cTnI
and its relation to outcome may be of interest, the main pur-
pose of our study was to determine whether early cTnI eleva-
tion is of clinically relevant importance.
Conclusion
We conclude that troponin elevation may be used as an early
marker of severity of illness and outcome, particularly in older
patients, but it is not an independent predictor of mortality.
Additional larger prospective studies will be required to deter-
mine if a single serum marker, reflecting myocardial injury,
could be established as an independent prognostic tool.
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